Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11939331 Tricyclic heterocycles as FGFR inhibitors

Patent 11939331 was granted and assigned to Incyte on March, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Evan Styduhar0

Xin Li0

Robert Swyka0

Wenqing Yao0

Oleg Vechorkin0

Date of Patent

March 26, 2024

0

Patent Application Number

178353310

Date Filed

June 8, 2022

0

Patent Citations

US Patent 7642255 Compounds and compositions as protein kinase inhibitors

0

US Patent 7648973 2-methylene-1α,25-dihydroxy-19,21-dinorvitamin D

0

US Patent 7943743 Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

0

US Patent 8008449 Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics

0

US Patent 8168757 PD-1 binding proteins

0

US Patent 8217149 Anti-PD-L1 antibodies, compositions and articles of manufacture

0

US Patent 8759398 Phosphorus binder composition for treatment of hyperphosphatemia

0

US Patent 6998408 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors

0

...

Patent Citations Received

US Patent 12122767 Bicyclic heterocycles as FGFR inhibitors

0

Patent Primary Examiner

0

CPC Code

0

0

0

0

0

0

0

0

...

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11939331 Tricyclic heterocycles as FGFR inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool